Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Intranasal esketamine combo tied to symptom improvement

Publish date:: May 21, 2019

Key clinical point: Pivotal study reports a modest benefit to symptoms when inhaled esketamine is combined with a new antidepressant in treatment-resistant depression.

Major finding: Combining esketamine with a new antidepressant led to a small improvement in symptoms, compared with the antidepressant alone (effect size, 0.30).

Study details: Results of a randomized, controlled trial (n = 223).

Disclosures: The study was funded by Janssen Research and Development. Dr. Sanacora was an investigator on previous Janssen-funded studies and has consulted for Janssen. Dr. Schatzberg has received research support from and consulted for Janssen, and has consulted for numerous other companies. Dr. Thase has received research support from Janssen and consulted for a wide range of pharmaceutical companies.

Citation:

Popova V et al. APA 2019, Am J Psychiatry. 2019 May. doi: 10.1176/appi.ajp.2019.19020172.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Depression

Social factors predicted peripartum depressive symptoms in Black women with HIV,

Teen affective disorders raise risk for midlife acute MI,

Divergent COVID-19 mental health impacts seen in Spain and China,

Watch for nonsuicidal self-injury in girls with ADHD, comorbidities,

Sleep EEG may predict later antidepressant response,